ID
33028
Descripción
Study ID: 101877 Clinical Study ID: SAS101877 Study Title: A randomised, open label, 5-way crossover study to assess the systemic exposure of FP and salmeterol from SERETIDE/ADVAIR 250 without spacer, with Aerochamber -Plus and with -Max spacer, with VOLUMATIC spacer and SERETIDE/ADVAIR 500 DISKUS/ACCUHALER in adult subjects with mild or intermittent asthma Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 1 Study Recruitment Status: Completed Generic Name: fluticasone propionate/salmeterol Trade Name: Advair DISKUS,Seretide Accuhaler; Viani,Seretide Diskus,Seretide Accuhaler,Seretide,Advair DISKUS Study Indication: Asthma The study consists of 5 treatment periods and a follow-up visit. The Screening includes Session 1 Treatment Period 1 includes Session 2 Treatment Period 2 includes Session 3 Treatment Period 3 includes Session 4 Treatment Period 4 includes Session 5 Treatment Period 5 includes Session 6 The Follow-up includes Session 7. This document contains the Non-Serious Adverse Events form. It has to be filled in if a Non-Serious Adverse Event occurs during study. Examples of an AE includes: Exacerbation of a chronic or intermittent pre-existing condition including either an increase in frequency and/or intensity of the condition. New conditions detected or diagnosed after investigational product administration even though it may have been present prior to the start of the study. Signs, symptoms, or the clinical sequelae of a suspected interaction. Signs, symptoms, or the clinical sequelae of a suspected overdose of either investigational product or a concomitant medication (overdose per se should not be reported as an AE/SAE). Examples of an AE does NOT include a/an: Medical or surgical procedure (e.g., endoscopy, appendectomy); the condition that leads to the procedure is an AE. Situations where an untoward medical occurrence did not occur (social and/or convenience admission to a hospital). Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the start of the study that do not worsen. The disease/disorder being studied, or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the sub1ect's condition.
Palabras clave
Versiones (2)
- 22/11/18 22/11/18 -
- 23/11/18 23/11/18 -
Titular de derechos de autor
GlaxoSmithKline
Subido en
23 de noviembre de 2018
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Systemic exposure of fluticasone propionate (FP) and salmeterol from different inhalation devices in adults with mild or intermittent asthma, (Study-)ID: 101877
Non-Serious Adverse Events
- StudyEvent: ODM
Descripción
Non-Serious Adverse Events
Alias
- UMLS CUI-1
- C1518404
Descripción
If YES, indicate following items. Any untoward medical occurrence in a patient or clinical investigation subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. For marketed medicinal products, this also includes failure to produce expected benefits (i.e., lack of efficacy), abuse or misuse.
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1518404
Descripción
Diagnosis only (if known) signs / symptoms (list one per line). Enter only the diagnosis (if known); otherwise each sign and symptom should be entered on a separate line If a diagnosis subsequently becomes available, then this should be entered and the signs and symptoms crossed out.
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C1518404
- UMLS CUI [1,2]
- C0011900
Descripción
day month year. Record the date of onset of the first occurrence of the AE .
Tipo de datos
date
Alias
- UMLS CUI [1,1]
- C0574845
- UMLS CUI [1,2]
- C1518404
Descripción
00:00-23:59 Record the exact time of onset of the AE.
Tipo de datos
time
Alias
- UMLS CUI [1,1]
- C0449244
- UMLS CUI [1,2]
- C1518404
Descripción
Record the maximum intensity that occurred over the duration of the event. Amend the intensity if it increases.
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1710066
Descripción
All AEs must be followed until the events are resolved, the condition stabilizes, the events are otherwise explained, or the subject is lost to follow-up. Indicate if the event was "Resolved" or "Resolved with sequelae". If the adverse event is ongoing at the time the subject completes the study or becomes lost to follow-up, the outcome must be recorded as "Not resolved". Also enter "Not resolved" if the AE was ongoing at the time of death, but was not the cause of death.
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1705586
Descripción
day month year. Record the date of resolution. This is the last date of occurrence of the AE. If the event resolved with sequelae, enter the date the subject's medical cond ition stabilized. Leave blank if the AE is "Not resolved".
Tipo de datos
date
Alias
- UMLS CUI [1]
- C2985918
Descripción
00:00-23:59 Record the exact lime of resolution of the AE.
Tipo de datos
time
Alias
- UMLS CUI [1,1]
- C0040223
- UMLS CUI [1,2]
- C2699488
- UMLS CUI [1,3]
- C1518404
Descripción
Indicate only for the specific event(s) that were directly responsible for the action taken with investigational product(s): None: lnvestigational product(s) continue(s) even though an adverse event has occurred. Dose adjusted: Dose is increased or decreased for one or more investigation al product(s). Temporarily interrupted: Administration of one or more invesligational product(s) was stopped temporarily but then restarted. Permanently discontinued: Administration of one or more investigalional product(s) was stopped permanently and not restarted. Not applicable: Subject was not receiving investigational product(s) when the event occurred (e.g., pre- or postdosing).
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C1704758
- UMLS CUI [1,2]
- C1518404
Descripción
Indicate only the event(s) directly responsible for the subject's withdrawal as indicated on the End of Study Record page.
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C2349954
- UMLS CUI [1,2]
- C1518404
Descripción
II is a regulatory requirement for investigators lo assess relationship lo invesligalional product(s) based on information available. The assessment should be reviewed on receipt of any new information and amended if necessary. "A reasonable possibility" is meant to convey that there are facts/evidence or arguments to suggest a causal relationship. Facts/evidence/arguments that may support ''A reasonable possibility" include , for example, a temporal relationship, a pharmacologically-predicted event, or positive dechallenge or rechallenge Confounding factors, such as concomitant medication, a concomitant illness, or relevant medical history, should also be considered.
Tipo de datos
text
Alias
- UMLS CUI [1,1]
- C0304229
- UMLS CUI [1,2]
- C0085978
- UMLS CUI [1,3]
- C1518404
Descripción
If you tick YES, fill in the SAE form!
Tipo de datos
text
Alias
- UMLS CUI [1]
- C1710056
Similar models
Non-Serious Adverse Events
- StudyEvent: ODM
C0011900 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C2699488 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
C1518404 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,2])
C0085978 (UMLS CUI [1,2])
C1518404 (UMLS CUI [1,3])
Sin comentarios